JP Morgan Initiates Coverage On C4 Therapeutics with Overweight Rating, Announces Price Target of $10

Benzinga Newsdesk www.benzinga.com Positive 59.7%

Neg 0% Neu 0% Pos 59.7%

JP Morgan analyst Anupam Rama initiates coverage on C4 Therapeutics (NASDAQ:CCCC) with a Overweight rating and announces Price Target of $10.